Lv51
1190 积分 2024-04-25 加入
656 A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY PHASE III CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF BISMUTH QUADRUPLE THERAPY CONTAINING TEGOPRAZAN COMPARED TO ESOMEPRAZOLE IN ERADICATING HELICOBACTER PYLORI IN CHINA
2天前
已完结
Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer
2天前
已完结
Efficacy of tegoprazan‐based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double‐blind, active‐controlled study
2天前
已完结
Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based quadruple therapy for Helicobacter pylori eradication: A multicenter, double-blind, randomized, phase 3 study
2天前
已完结
EFFICACY AND COST-EFFECTIVENESS, COMPARISON OF 7-DAYS VONOPRAZAN VERSUS 14-DAYS ESOMEPRAZOLE BASED TRIPLE THERAPIES FOR TREATING HELICOBACTER PYLORI INFECTION IN PAKISTANI POPULATION: A RANDOMIZED CLINICAL TRIAL
4天前
已完结
IDDF2024-ABS-0298 Efficacy and safety of potassium competitive acid blocker based therapies vs proton-pump inhibitor based therapies in H. pylori eradication: a meta-analysis
4天前
求助中
IDDF2024-ABS-0298 Efficacy and safety of potassium competitive acid blocker based therapies vs proton-pump inhibitor based therapies in H. pylori eradication: a meta-analysis
5天前
已关闭
Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial
9天前
已完结
IDDF2024-ABS-0298 Efficacy and safety of potassium competitive acid blocker based therapies vs proton-pump inhibitor based therapies in H. pylori eradication: a meta-analysis
10天前
已关闭
Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients
23天前
已完结
皖公网安备34019202002308
